Search

Displaying all 2 results
DrugBest match

Osimertinib

go.drugbank.com/drugs/DB09330
ApprovedInvestigational

Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals. Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutat...

  1. Drug

    Becotatug

    go.drugbank.com/drugs/DB19069
    Investigational

    Becotatug is under investigation in clinical trial NCT06380348 (JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung